NEWLINK GENETICS CORP Business Operations Contracts & Agreements
39 Contracts & Agreements
- Agency Agreements (2 contracts)
- Collaboration Agreements (7)
- Development Agreements (27)
- Sales Agreements (1)
- Services Agreements (1)
- Settlement Agreements (1)
- Amendment to License and Collaboration Agreement dated (Filed With SEC on March 5, 2019)
- Amendment No. 3 to License and Collaboration Agreement by and between the Registrant and Merck Sharp & Dohme Corp., dated October 9, 2018 (Filed With SEC on November 2, 2018)
- Amendment to License and Collaboration Agreement by and between Merck Sharp & Dohme Corp., dated May 10, 2018 (Filed With SEC on August 6, 2018)
- Controlled Equity OfferingSM Sales Agreement, dated March 12, 2018, by and between NewLink Genetics Corporation and Cantor Fitzgerald & Co (Filed With SEC on March 13, 2018)
- Amendment to License and Collaboration Agreement dated December 5, 2017 by and among the Company, BioProtection Systems Corporation and Merck Sharp & Dohme Corp (Filed With SEC on March 5, 2018)
- RESEARCH SERVICES AGREEMENT (Filed With SEC on April 29, 2016)
- FIRST AMENDED AND RESTATED CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation (Filed With SEC on February 29, 2016)
- FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN NEWLINK GENETICS CORPORATION, NEWLINK GLOBAL, GENENTECH, INC. AND F. HOFFMANN-LA ROCHE LTD OF OCTOBER 16,... (Filed With SEC on May 11, 2015)
- LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on March 16, 2015)
- Amendment to Development and Manufacturing Terms and Conditions (Filed With SEC on November 10, 2014)
- License and Collaboration Agreement by and between NewLink Genetics Corporation and NewLink Global and Genentech, Inc. and F. Hoffmann-La Roche Ltd October 16, 2014 (Filed With SEC on November 10, 2014)
- Development and Process Transfer Program Leading to Commercial Manufacturing for algenpantucel-L HyperAcute" Pancreas Technical Transfer, Verification / Process Development,... (Filed With SEC on August 5, 2014)
- CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation (Filed With SEC on August 5, 2014)
- PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH (Filed With SEC on May 10, 2012)
- SETTLEMENT AGREEMENT (Filed With SEC on March 28, 2012)
- HER MAJESTY THE QUEEN IN RIGHT OF CANADA, as represented by the Minister of Health, acting through the Public Health Agency of Canada (Canada) (Filed With SEC on November 8, 2011)
- AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on November 8, 2011)
- AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on November 8, 2011)
- AMENDMENT #8 To Letter of Intent for Proposed CRADA #02166 Preclinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)
- HER MAJESTY THE QUEEN IN RIGHT OF CANADA, as represented by the Minister of Health, acting through the Public Health Agency of Canada (Canada) (Filed With SEC on October 4, 2011)
- AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)
- AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent (Filed With SEC on October 4, 2011)
- DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER RESEARCH TRIANGLE PARK DIVISION P.O. BOX 12211 RESEARCH TRIANGLE PARK, NORTH... (Filed With SEC on February 28, 2011)
- DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER (Filed With SEC on February 28, 2011)
- DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER (Filed With SEC on February 28, 2011)
- AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on February 28, 2011)
- $6,000,000 IOWA VALUES FUND (IVF) CONTRACT BY AND BETWEEN NEWLINK GENETICS CORPORATION AND THE IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT DATED AS OF MARCH 18, 2005 (Filed With SEC on December 21, 2010)
- AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*] (Filed With SEC on December 21, 2010)
- Cooperative Research and Development Agreement (CRADA #1901) [*] NCI Principal Investigator John C. Morris, M.D. Metabolism Branch, CCR, NCI Collaborator PrincipalInvestigator... (Filed With SEC on December 21, 2010)
